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Abstract
Background: Malignant glioma is a rare cancer with poor survival. The influence of diet and antioxidant intake on 
glioma survival is not well understood. The current study examines the association between antioxidant intake and 
survival after glioma diagnosis.
Methods: Adult patients diagnosed with malignant glioma during 1991-1994 and 1997-2001 were enrolled in a 
population-based study. Diagnosis was confirmed by review of pathology specimens. A modified food-frequency 
questionnaire interview was completed by each glioma patient or a designated proxy. Intake of each food item was 
converted to grams consumed/day. From this nutrient database, 16 antioxidants, calcium, a total antioxidant index and 
3 macronutrients were available for survival analysis. Cox regression estimated mortality hazard ratios associated with 
each nutrient and the antioxidant index adjusting for potential confounders. Nutrient values were categorized into 
tertiles. Models were stratified by histology (Grades II, III, and IV) and conducted for all (including proxy) subjects and for 
a subset of self-reported subjects.
Results: Geometric mean values for 11 fat-soluble and 6 water-soluble individual antioxidants, antioxidant index and 3 
macronutrients were virtually the same when comparing all cases (n = 748) to self-reported cases only (n = 450). For 
patients diagnosed with Grade II and Grade III histology, moderate (915.8-2118.3 mcg) intake of fat-soluble lycopene 
was associated with poorer survival when compared to low intake (0.0-914.8 mcg), for self-reported cases only. High 
intake of vitamin E and moderate/high intake of secoisolariciresinol among Grade III patients indicated greater survival 
for all cases. In Grade IV patients, moderate/high intake of cryptoxanthin and high intake of secoisolariciresinol were 
associated with poorer survival among all cases. Among Grade II patients, moderate intake of water-soluble folate was 
associated with greater survival for all cases; high intake of vitamin C and genistein and the highest level of the 
antioxidant index were associated with poorer survival for all cases.
Conclusions: The associations observed in our study suggest that the influence of some antioxidants on survival 
following a diagnosis of malignant glioma are inconsistent and vary by histology group. Further research in a large 
sample of glioma patients is needed to confirm/refute our results.
Background
Mortality following diagnosis of malignant brain tumors
varies by histologic type and other risk factors. Between
1991 and 2000, adults diagnosed with malignant glioma
had median survival times that ranged from 7 months for
highest grade tumors (gliomablastoma multiforme) to 91
months for lower grade tumors (oligodendroglioma) [1].
The majority of glioma patients are diagnosed with
gliomablastoma multiforme (GBM), and 5-year survivor-
ship is < 3%. Among patient characteristics that are asso-
ciated with differential survival rates following a glioma
diagnosis, only age appears to be as strong a predictor as
histology [2]. Other risk factors such as tumor location
and the magnitude of tumor resection [3-6], molecular
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and genetic markers [7-13], and Karnofsky performanace
status [14-20] have been examined in a number of studies
of survival in glioma patients. However, the potential
association of diet, in general, and antioxidant intake, in
particular, with survival after glioma diagnosis in human
populations has been only sparsely investigated [21,22].
Oxygen-derived free radicals produced by lipid peroxi-
dation are believed to play an important role in cancer
development [23,24]. Antioxidants can act as reducing
agents to prevent oxidative reactions by either scavenging
reactive oxygen species (ROS) or inhibiting cellular sig-
naling enzymes such as protein kinase C (PKC) [25,26].
Proliferation of malignant gliomas can be induced by
PKC isoforms through several signaling pathways [27-
30]. Endogenous antioxidant enzymes are one of the
brain's natural defense mechanisms to remove the highly
toxic hydrogen peroxide molecule; decreased activity of
glutathione peroxidase and reductase have been found in
glioblastoma tissue [31-33]. Dietary antioxidants, includ-
ing isoflavones and polyphenols, have been shown in lab-
oratory studies to enhance growth restriction of cancer
cells in general [34] and glioma cells in particular [35,36].
However other studies have indicated that high concen-
trations of non-enzymatic antioxidants, including carote-
noids and flavonoids, can exhibit pro-oxidant behavior,
particularly in the presence of redox-active metals (cop-
per, iron) and a high pH [26,37]. There is also evidence
that the combination of cigarette smoking and antioxi-
dant intake can diminish the effects of radiotherapy for
certain cancers [38].
With respect to a potential effect of antioxidants on
survival of patients with gliomas, two opposing hypothe-
ses can be formulated. First, because brain tissues are one
of the most oxidative environments and therefore suscep-
tible to radiation damage, antioxidants may protect nor-
mal brain tissues from radiation damage and lead to
better survival [39]. On the other hand, antioxidants may
make the glioma more resistant to tumor killing by radia-
tion [40], possibly leading to poorer patient survival.
Given this lack of consensus it is important then to exam-
ine the potential association between antioxidant intake
and patient survival in a large population-based cohort of
adults diagnosed with malignant glioma.
In the current study, we examine patterns of survival
after a diagnosis of malignant glioma in relation to intake
of dietary antioxidants and other nutrients. We estimate
the contribution of antioxidants and other nurtients, both
separately and in combination with each other, to glioma
survival adjusting for known risk factors and confound-
ers. Our results are stratified by histology group and by
type of interview, i.e. patient self-report or interview with
the patient's designated proxy.
Methods
Study population
The ascertainment of glioma cases and study subject eli-
gibility requirements have been described in detail by
Wiemels et al. [41] and Wrensch et al. [42]. In summary,
any adult (ages ≥ 20) with an incident diagnosis of glioma
(ICD-O morphology codes 9380-9481) between August
1991 and April 1994 (series 1) and May 1997 and August
1999 (series 2) residing anywhere in the six county San
Francisco-Oakland MRSA ould meet study eligibility cri-
teria [1]. Potential glioma cases were identified using
rapid case ascertainment (RCA) provided by a Surveil-
lance Epidemiology and End Results (SEER) participating
registry, the Northern California Cancer Center (NCCC).
Subjects or their designated proxies provided written
consent to obtain and review pathology specimens and
records to confirm a glioma diagnosis. Consenting
patients or their proxies completed surveys concerning a
number of characteristics and potential risk factors.
Other glioma cases were not included as study subjects
because either consent was not obtained, neuropathology
review was not possible or revealed a diagnosis not eligi-
ble for the study.
Neuropathology Review
Pathology records and specimens, provided by the diag-
nosing hospitals, were reviewed by a neuropathologist
[43]. WHO criteria [44] were used to classify all tumors.
GBM corresponds to WHO grade IV, anaplastic astrocy-
toma (AA) to WHO grade III, and astrocytoma to WHO
grade II.
Determination of Vital Status
NCCC-SEER, which routinely ascertains vital status via
California State mortality tapes and the National Death
Index, provided vital status for the study subjects in
December 2002 [1]. For cases not known to be deceased,
a letter was sent to the last known address, followed by a
telephone call. Mortality was updated from SEER in
December, 2008. For a small number of cases who could
not be located, date of last contact (as determined by
NCCC-SEER) was used. Patients not known to be dead
were censored at date of last contact.
Dietary questionnaires and interviews
Series I
Eligible cases or designated proxies were given an in-per-
son interview at the subjects' home or other location of
their choice [45]. Subjects received a dietary question-
naire in advance, which was collected or completed at the
in-person interview. The temporal period for all ques-
tions was the year preceding the glioma diagnosis.
A detailed description of the Series I questionnaire has
been provided in Tedeschi-Blok et al [46]. Briefly, a 79-
item food-frequency questionnaire was modified fromDeLorenze et al. BMC Cancer 2010, 10:215
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the US National Cancer Institutes' (Block's) Health Habits
and History Questionnaire [47]and the Los Angeles
Glioma and Meningioma Study Questionnaire [48]. Sub-
jects reported their usual frequencies of consumption of
each food item. The frequency choices included: 'never',
'less than 1 per month', '1 per month', '2-3 per month', '1
per week', '2 per week', '3-4 per week', '5-6 per week', '1
per day', and '2 or more per day'. Portion sizes were not
asked, but were estimated using gender- and age- specific
values from the Block and colleagues' National Cancer
Institute's Health Habits and History Questionnaire [47].
Series II
Series II eligible cases or designated proxies were
approached in a manner similar to Series I. However
instead of receiving a self-administered diet question-
naire in advance, interviewers asked the diet questions in
Series II. The 96-item Series II diet questionnaire was
m o d i f i e d  f r o m  t h e  U S  N a t i o n a l  C a n c e r  I n s t i t u t e s '
(Block's) Health Habits and History Questionnaire. Mod-
ifications [47]. The frequency choices included: 'never or
less than 1 per month', '1 per month', '2-3 per month, '1
per week', '2 per week', '3-4 per week', '5-6 per week', '1
per day'.
Series I & II
For eligible subjects who did not wish to participate in the
full interview, a 5-minute phone interview was adminis-
tered using an abbreviated questionnaire asking basic
demographic and dietary questions. This permitted eval-
uation of major differences in dietary consumption
between those cases who participated in the full inter-
view and those who did not.
Dietary analyses
Assignment of reported food frequency choices into lev-
els of specific nutrients has been previously described in
detail by Tedeschi-Blok et al [46]. Intake of each food
item was converted to grams consumed per day by apply-
ing an appropriate algorithm for each series. For both
series, a nutrient database included a total of 27 nutrients
per 100 grams for each food item. Of the 27 nutrients, 16
antioxidants plus calcium and 3 macronutrients were
available for our survival analysis. A total daily antioxi-
dant index intake was calculated by summing the product
of grams consumed over all food items and units of anti-
oxidant index per gram from an antioxidant index data-
base for fruit, vegetable, juice and tea food items [49-51].
Antioxidant index values were units of micromoles
Trolox equivalents per gram of food. Trolox equivalents
per gram of food were measured by the oxygen radical
absorbance capacity (ORAC) assay [50,51].
Use of Alcohol and Tobacco
The Series I and II surveys included questions concerning
alcohol consumption (age at first drink; weekly consump-
tion of wine, beer and liquor) and cigarette smoking (age
began smoking; number of cigarettes per day; number of
years of active smoking). Because both alcohol and ciga-
rette smoke are oxidants and have been shown to be
related to oxidative stress in the brain and the expression
of antioxidants (e.g., vitamin C and beta-carotene)
[52,53], responses to these questions were included in the
study analyses.
Determination of Treatment Information
Treatment information and other clinical characteristics
was obtained from NCCC-SEER, medical record abstrac-
tion, and a clinical trials database from UCSF. NCCC-
SEER treatment information includes summary data for
surgery, radiation, and chemotherapy. NCCC-SEER pro-
vided a summary of curative treatment information given
as the first course of therapy following diagnosis. Infor-
mation from medical record abstraction included Kar-
nofsky performance status (KPS) at time of diagnosis,
tumor location, surgical resection, radiation, and chemo-
therapy. The UCSF Neuro-Oncology Service database
contained these data items for patients entered in clinical
trials. Since KPS was not available for many subjects, it
was not included in these analyses.
Statistical Analysis
Preliminary data analysis included an examination of the
univariate distributions of nutrients and potential con-
founders including patient demographics (age, gender,
race, education, income, marital status), histology group,
treatment, series, comorbid conditions (epilepsy, chicken
pox, shingles, allergies), Karnofsky score, alcohol and
tobacco use for all glioma cases (including interviews
completed by a designated proxy) and for only cases who
were interviewed directly (no proxy). Several of these
potential confounders, age at diagnosis in particular, have
been previously reported as significantly associated with
mortality following a glioma diagnosis in a survival analy-
sis of the same patients included in the current study [1].
Descriptive statistics included geometric mean nutrient
intake (given the skewness in nutrient distributions)
adjusted for total calories. Adjusted geometric means
were obtained via a linear regression of log nutrient on
calories and calculating the anti-log of the least squares
mean. Preliminary analyses also included an examination
of each nutrient and potential confounder in relation to
survival via Kaplan-Meier survival curves and log-rank
tests.
Based upon the results of the univariate analyses, Cox
proportional hazards models were used for point and
interval estimation of mortality hazard ratios associated
with each antioxidant, antioxidant index, and other nutri-
ents adjusting for potential confounders. Regression anal-
y s e s  w e r e  s t r a t i f i e d  b y  g r a d e  a n d  c o n d u c t e d  u s i n g  a l lDeLorenze et al. BMC Cancer 2010, 10:215
http://www.biomedcentral.com/1471-2407/10/215
Page 4 of 15
(including proxy interviews) glioma cases and in the sub-
set of self-reported cases. Primary analyses examined
nutrients categorized in tertiles to allow examination of
dose response and threshold effects. Given previous stud-
ies in this and other cohorts [1,3-6,15,54], age and treat-
ment (radiation, chemotherapy, surgery: all as
dichotomous yes/no) were a priori included in all regres-
sion analyses. As is standard in analyses of nutrients in
relation to health outcomes, total caloric intake was also a
priori included in all regression models. Given results
from our preliminary analyses as well as evidence from
previous studies of risk factors [38,41,45] associated with
malignant glioma, education, marital status, alcohol (age
at first alcoholic drink) and tobacco use (pack years of
c i g a r e t t e  s m o k i n g )  w e r e  i n c l u d e d  a s  c o v a r i a t e s  i n  t h e
regression analysis. In addition, for any significant base-
model adjusted nutrient survival associations that were
observed, we did a check for other potential confounders
(e.g. income, comorbid conditions, protein intake),
although none were found to appreciably change hazard
ratio (HR) estimates. All tests of significance in this analy-
sis were 2-sided, and all statistical analyses were com-
pleted using SAS statistical software (Version 9.1, Cary,
NC). Final models were selected based upon statistical
significance.
Results
The distribution of demographic, clinical and behaviorial
characteristics is presented in Table 1, which is stratified
for all cases (including interviews completed by proxy)
and for self-reported cases (case was interviewed) only.
Self-reported (SR) cases were somewhat younger in age at
the time of diagnosis when compared to all cases. The
distribution of gender and race categories was similar in
both groups. Self-reported cases were more likely to have
completed at least one year of college, had a higher pro-
portion of Grade II (histology) tumors, and a lower pro-
portion of Grade IV tumors in comparison to all cases.
Both groups showed similar distributions in the catego-
ries for age at first alcoholic drink and smoking (pack-
years). For glioma-related treatment the self-reported
cases had somewhat higher rates of receiving surgical
resection, radiotherapy and chemotherapy when com-
pared to all cases.
Geometric means of the total daily antioxidants and
other nutrients consumed adjusted for total calories
among all cases are shown in Table 2. The geometric
mean values for the Antioxidant Index are virtually the
same when comparing all cases to self-reported cases
only. A similar pattern is observed for most of the 11 fat-
soluble and 7 water-soluble individual antioxidants and
the 3 macronutrients listed in Table 2.
Hazard ratios for tertiles of daily intake of fat-soluble
antioxidants adjusted for age at glioma diagnosis, educa-
tion, marital status, treatment, cigarette smoking (pack-
years), alcohol (age at first alcoholic drink), and total cal-
ories, stratified by proxy status (all cases vs self-reported
cases only) and histology group (Grade II, III, and IV) are
presented in Table 3. Examining these results for those
that were statistically significant, we found that the haz-
ard ratio for moderate intake of lycopene (HR = 2.31, 95%
CI = 1.12 to 4.75, for second tertile compared to lowest
tertile, in self-reported cases only) was elevated within
the Grade II histology group. Similarly moderate intake of
lycopene among patients in the Grade III histology group
was associated with poorer survival. Hazard ratios for
high intake of vitamin E (HR = 0.37, 95% CI = 0.17 to
0.81, highest tertile compared to lowest tertile, in all
cases) and for both moderate and high intake of secoiso-
lariciresinol (for second tertile and for highest tertile
compared to lowest tertile, in all cases) among Grade III
patients indicate enhanced survival. Moderate intake of
alpha-carotene (HR = 2.12, 95% CI = 1.08 to 4.18, for sec-
ond tertile compared to lowest tertile, in self-reported
cases only) among Grade III patients was associated with
poorer survival. In the Grade IV histology group, moder-
ate to high intake of cryptoxanthin (for second tertile and
for highest tertile compared to lowest tertile, in all cases),
moderate intake of matairesonal (for second tertile com-
pared to lowest tertile, in all cases), and high intake of
secoisolariciresinol (for highest tertile compared to low-
est tertile, in all cases) was associated with poorer sur-
vival.
Table 4 presents hazard ratios for tertiles of daily intake
of water-soluble antioxidants adjusted for the same set of
covariates as the models shown in Table 3. Among Grade
II patients, moderate intake of folate was associated with
enhanced survival (HR = 0.45, 95% CI = 0.20 to 0.99, for
second tertile compared to lowest tertile, in all cases).
Moderate intake of formonoetin among Grade III
patients was also associated with enhanced survival.
Among Grade IV patients, high intake of vitamin C and
genistein as well as moderate intake of formonoetin, in all
cases, was associated with poorer survival.
Hazard ratios for tertiles of the Antioxidant Index and
the macronutrients are presented in Table 5.
Moderate intake of total protein (HR = 0.44, 95% CI =
0.20 to 0.95, for second tertile compared to lowest tertile,
in self-reported cases only; HR = 0.40, 95% CI = 0.18 to
0.93, for second tertile compared to lowest tertile, in all
cases) among Grade II patients was associated with
enhanced survival; a similar result was observed among
Grade IV patients with high intake of total protein.
Among Grade III patients, high intake of total choles-
terol, in all cases, was associated with better survival.
M o d e r a t e  i n t a k e  o f  t o t a l  c h o l e s t e r o l ,  i n  a l l  c a s e s ,  w a s
associated with poorer survival among Grade IV patients.
The only statistically significant results for AntioxidantDeLorenze et al. BMC Cancer 2010, 10:215
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Index were observed in Grade IV patients where the
highest tertile of intake, in all cases, (HR = 1.36, 95% CI =
1.02 to 1.81) was associated with poorer survival.
Discussion
Intake of dietary antioxidants and other nutrients may be
part of the risk profile associated with enhanced or
diminished survival following a diagnosis of glioma. Our
study results offer some insights among glioma patients
diagnosed with Grade II and Grade III tumors, and possi-
bly Grade IV tumors. Our analysis included a large
glioma patient cohort recruited over a 9-year interval
when treatment practices remained generally unchanged.
Our study cohort is comparable to other cohorts of
glioma patients in the distribution of patient and clinical
characteristics such as age at diagnosis and pattern of
treatment.
Although most individual antioxidant effect estimates
in our analyses were not statistically significant, generally
the magnitude and direction of the hazard ratios in all
three histology groups was consistent across self-
reported cases and all cases. Some inconsistent results,
however, were observed where moderate intake of lyco-
pene was associated with poorer survival among the self-
reported cases only in both Grade II and Grade III
patients. A similar result for moderate intake of alpha-
carotene was observed in Grade III patients. Among
these two carotenoids, lycopene has been shown to
inhibit progression of prostate, breast and lung cancer
cell lines [26]. However while carotenoids in general
exhibit antioxidant behavior at low oxygen partial pres-
Table 1: Distribution of patient characteristics; San Francisco Bay Area Adult Glioma Study, 1991-2000
 Characteristics  All cases (N = 748)  Self-reported cases (N = 450)
Age (median ± SE) 55.7 ± 0.6 49.8 ± 0.7
Gender (% male) 57.1% 59.1%
Ethnicity (% White) 83.4% 84.2%
Education
< 12 years 12.2% 6.4%
High school graduate 24.2% 20.9%
≥ 1 year college 63.6% 72.7%
Histology Group
Grade II† 19.1% 28.2%
Grade III‡ 17.4% 19.3%
Grade IV* 63.5% 52.4%
Treatment
Surgical Resection 83.0% 91.8%
Radiotherapy 73.7% 83.1%
Chemotherapy 20.3% 26.9%
Age at first drink
Never drank alcohol 9.2% 8.0%
<18 years old 30.4% 31.3%
18 - 20 years old 33.2% 34.7%
≥21 years old 26.6% 26.0%
Unknown 0.7% 0%
Total Packyears
Never smoked 43.5% 46.0%
> 0 to ≤ 18.5 25.4% 30.0%
> 18.5 25.9% 22.0%
Unknown 5.2% 2.0%
† includes 44 astrocytomas, 63 oligodendrogliomas, 36 oligoastrocytomas.
‡ includes 90 astrocytomas, 26 oligodendrogliomas, 14 oligoastrocytomas.
*all (n = 475) glioblastomas.DeLorenze et al. BMC Cancer 2010, 10:215
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sures (below 150 Torr), they can lose antioxidant poten-
tial and become pro-oxidant at higher pressures of
oxygen [26].
Significantly enhanced survival estimates were
o bse rved f or  m ode ra t e  in ta k e  o f  f ola t e  as  we l l as t ota l
protein intake among Grade II patients; this was consis-
tent across self-reported cases and all cases. Among
Grade III patients, significantly enhanced survival
occurred with high intake of vitamin E, moderate intake
of formononetin, and both moderate and high intake of
secoisolariciresinol in all cases. Laboratory analysis has
shown that vitamin E (particularly α-tocopheryl succi-
nate and tocopherols) inhibits the angiogenic factor, vas-
cular endothelial growth factor (VEGF), which is induced
by glioma tumors, thus having the potential to limit
glioma cell proliferation [55]. Gamma-tocopherols have
also been shown to decrease PKC upstream and retino-
blastoma(Rb) phosphorylation downstream controlling
cell cycle production in C-6 glioma cells [56]. Tedeschi-
Blok et al [46] observed a chemopreventive effect for
moderate intake of vitamin E and formononetin, and high
intake of secoisolariciresinol in a comparison of all (not
stratified by histology group) glioma cases (same cohort
as current study) vs controls.
Among Grade IV patients the magnitude of the hazard
ratios was generally consistent across self-reported cases
and all cases. Among all Grade IV cases, a number of
antioxidants and other nutrients were significantly asso-
ciated with poorer survival. These included high intake of
the total Antioxidant Index, vitamin C, genistein, and
Table 2: Antioxidant and nutrient geometric mean values (adjusted for total calorie intake)
Nutrient All cases (N = 748) Self-reported cases (N = 450)
Fat-soluble:
Vitamin E (mg) 7.8 7.6
Carotenoids (mcg) 3441.1 3327.4
Alpha-carotene (mcg) 589.9 554.8
Beta-carotene (mcg) 2783.5 2696.4
Lutein (mcg) 1889.5 1906.2
Lycopene (mcg) 1230.0 1277.1
Cryptoxanthin (mcg) 104.6 110.2
Coumestrol (mcg) 107.7 111.3
Matairesinol (mcg) 23.4 23.6
Secoisolariciresinol (mcg) 105.9 105.4
Linoleic acid (g) 11.2 10.9
Water-soluble:
Vitamin C (mg) 107.5 108.6
Formononetin (mcg) 14.3 15.2
Genistein (mcg) 230.8 248.3
Daidzein (mcg) 352.1 370.8
Biochanin A (mcg) 22.8 23.4
Calcium (mg) 642.6 626.3
Folate (mcg) 359.7 355.9
Antioxidant index 2442.9 2445.8
Macronutrients:
Total Protein (g) 59.8 58.6
Total Fat (g) 58.3 56.0
Total Cholesterol (mg) 210.4 202.8
Total Kcal (unadjusted) 1634.0 1599.8D
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Table 3: Associations between intake of fat-soluble antioxidants and survival following glioma diagnosis†, stratified by histology group
Nutrient (unit) Tertiles All or self-report 
(SR) only
Grade II Grade III Grade IV
(143 cases, 72 deaths) (130 cases, 103 deaths) (475 cases, 473 deaths)
Lower
limit
Upper
limit
HR 95% CI HR 95% CI HR 95% CI
Vitamin E (mg)
T1: 0.8 to 6.4 ALL 1 1 1
T2: 6.5 to 9.4 1.00 (0.44-2.27) 1.02 (0.60-1.74) 1.15 (0.89-1.50)
T3: 9.5 to 42.1 1.05 (0.33-3.33) 0.37* (0.17-0.81) 0.81 (0.58-1.12)
T1: 0.8 to 6.4 SR 1 1 1
T2: 6.5 to 9.4 0.87 (0.38-2.01) 1.75 (0.83-3.69) 1.06 (0.74-1.53)
T3: 9.5 to 42.1 0.82 (0.23-2.95) 1.06 (0.38-2.98) 0.97 (0.62-1.51)
Alpha-carotene (mcg)
T1: 7.4 to 427.1 ALL 1 1 1
T2: 428.6 to 916.1 0.64 (0.29-1.40) 1.44 (0.81-2.56) 0.99 (0.76-1.28)
T3: 917.8 to 17008.2 1.10 (0.55-2.22) 0.91 (0.48-1.72) 1.06 (0.80-1.40)
T1: 7.4 to 427.1 SR 1 1 1
T2: 428.6 to 916.1 0.65 (0.28-1.53) .12* (1.08-4.18) 0.88 (0.60-1.27)
T3: 917.8 to 17008.2 1.20 (0.57-2.53) 1.18 (0.57-2.45) 1.18 (0.81-1.72)
Beta-carotene (mcg)
T1: 257.7 to 2070.1 ALL 1 1 1
T2: 2070.2 to 3754.1 0.86 (0.43-1.74) 0.95 (0.54-1.68) 1.08 (0.84-1.39)
T3: 3757.6 to 39807.1 0.92 (0.45-1.90) 0.76 (0.37-1.54) 1.11 (0.85-1.46)
T1: 257.7 to 2070.1 SR 1 1 1
T2: 2070.2 to 3754.1 0.79 (0.36-1.71) 1.36 (0.64-2.90) 1.06 (0.74-1.53)
T3: 3757.6 to 39807.1 1.08 (0.53-2.21) 1.45 (0.61-3.48) 0.97 (0.66-1.41)
Carotenoids (mcg)
T1: 303.0 to 2501.5 ALL 1 1 1
T2: 2503.5 to 4658.0 0.89 (0.43-1.84) 1.05 (0.60-1.82) 1.11 (0.87-1.43)
T3: 4662.2 to 51458.1 0.91 (0.46-1.82) 0.68 (0.33-1.41) 1.18 (0.89-1.55)
T1: 303.0 to 2501.5 SR 1 1 1D
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T2: 2503.5 to 4658.0 0.74 (0.34-1.64) 1.70 (0.84-3.46) 1.13 (0.78-1.63)
T3: 4662.2 to 51458.1 1.02 (0.50-2.06) 1.21 (0.50-2.90) 1.02 (0.69-1.50)
Lutein (mcg)
T1: 31.3 to 1285.5 ALL 1 1 1
T2: 1288.6 to 2687.6 0.69 (0.36-1.35) 0.60 (0.35-1.02) 0.96 (0.74-1.23)
T3: 2694.2 to 51290.4 0.56 (0.26-1.18) 1.03 (0.53-2.01) 1.19 (0.92-1.53)
T1: 31.3 to 1285.5 SR 1 1 1
T2: 1288.6 to 2687.6 0.70 (0.35-1.43) 1.11 (0.55-2.26) 1.06 (0.73-1.53)
T3: 2694.2 to 51290.4 0.65 (0.30-1.41) 1.86 (0.72-4.78) 1.07 (0.74-1.53)
Lycopene (mcg)
T1: 0.0 to 914.8 ALL 1 1 1
T2: 915.8 to 2118.3 1.78 (0.92-3.46) 1.33 (0.77-2.31) 1.27 (0.99-1.62)
T3: 2121.5 to 26788.8 0.81 (0.37-1.80) 0.70 (0.36-1.36) 1.10 (0.85-1.44)
T1: 0.0 to 914.8 SR 1 1 1
T2: 915.8 to 2118.3 2.31* (1.12-4.75) 2.17* (1.02-4.62) 1.10 (0.77-1.57)
T3: 2121.5 to 26788.8 1.00 (0.41-2.44) 2.31 (0.98-5.43) 1.00 (0.69-1.44)
Cryptoxanthin (mcg)
T1: 0.0 to 79.8 ALL 1 1 1
T2: 80.2 to 180.3 1.52 (0.70-3.29) 0.66 (0.37-1.18) 1.34* (1.04-1.73)
T3: 180.4 to 1437.2 0.92 (0.39-2.17) 1.24 (0.66-2.33) 1.57* (1.20-2.06)
T1: 0.0 to 79.8 SR 1 1 1
T2: 80.2 to 180.3 1.83 (0.86-3.92) 1.04 (0.51-2.14) 1.19 (0.82-1.72)
T3: 180.4 to 1437.2 0.85 (0.35-2.08) 1.14 (0.52-2.51) 1.32 (0.90-1.93)
Coumestrol (mcg)
T1: 3.0 to 83.4 ALL 1 1 1
T2: 84.1 to 145.3 0.99 (0.51-1.90) 0.70 (0.38-1.30) 1.13 (0.88-1.45)
T3: 145.5 to 1315.3 0.77 (0.33-1.75) 1.06 (0.60-1.87) 1.16 (0.88-1.54)
T1: 3.0 to 83.4 SR 1 1 1
T2: 84.1 to 145.3 1.11 (0.56-2.21) 1.41 (0.67-2.96) 0.98 (0.68-1.40)
T3: 145.5 to 1315.3 0.73 (0.29-1.82) 0.96 (0.45-2.05) 1.06 (0.72-1.57)
Matairesinol (mcg)
T1: 0.1 to 17.6 ALL 1 1 1
T2: 17.7 to 34.5 1.17 (0.55-2.49) 0.88 (0.51-1.52) 1.38* (1.08-1.77)
Table 3: Associations between intake of fat-soluble antioxidants and survival following glioma diagnosis†, stratified by histology group (Continued)D
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T3: 34.6 to 218.6 0.78 (0.36-1.69) 0.86 (0.48-1.54) 1.20 (0.92-1.57)
T1: 0.1 to 17.6 SR 1 1 1
T2: 17.7 to 34.5 1.14 (0.52-2.50) 1.27 (0.59-2.73) 1.34 (0.95-1.89)
T3: 34.6 to 218.6 0.88 (0.38-2.04) 1.00 (0.48-2.09) 1.07 (0.74-1.55)
Secoisolariciresinol (mcg)
T1: 6.3 to 87.3 ALL 1 1 1
T2: 87.4 to 146.0 1.25 (0.60-2.61) 0.54* (0.31-0.93) 1.04 (0.81-1.33)
T3: 146.1 to 698.4 1.95 (0.93-4.10) 0.48* (0.25-0.92) 1.32* (1.02-1.72)
T1: 6.3 to 87.3 SR 1 1 1
T2: 87.4 to 146.0 1.19 (0.52-2.73) 0.75 (0.38-1.49) 0.83 (0.58-1.21)
T3: 146.1 to 698.4 1.41 (0.63-3.15) 0.51 (0.22-1.19) 0.95 (0.66-1.36)
Linoleic acid (g)
T1: 1.6 to 8.9 ALL 1 1 1
T2: 9.0 to 14.6 1.21 (0.57-2.58) 1.15 (0.66-2.02) 1.03 (0.80-1.32)
T3: 14.7 to 57.7 0.95 (0.35-2.60) 0.50 (0.25-1.01) 0.87 (0.63-1.19)
T1: 1.6 to 8.9 SR 1 1 1
T2: 9.0 to 14.6 1.14 (0.51-2.53) 0.88 (0.41-1.89) 0.85 (0.60-1.21)
T3: 14.7 to 57.7 1.17 (0.41-3.35) 0.59 (0.23-1.52) 0.96 (0.60-1.54)
† adjusted for reporting status (all cases vs self reported cases only), age at diagnosis (<48,48-65,>65), treatment (radiation, chemo, surgery - yes/no), education (<12, 12, >12), marital status (yes/
no), total calories (continuous), pack years (median = 18.5), and age at first alcoholic drink (<18,18-20,>20).
* p < 0.05
Table 3: Associations between intake of fat-soluble antioxidants and survival following glioma diagnosis†, stratified by histology group (Continued)D
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Table 4: Associations between intake of water-soluble antioxidants and survival following glioma diagnosis†, stratified by histology group
Nutrient (unit) Tertiles All or self-report 
(SR) only
Grade II Grade III Grade IV
(143 cases, 72 deaths) (130 cases, 103 deaths) (475 cases, 473 deaths)
Lower
limit
Upper
limit
HR 95% CI HR 95% CI HR 95% CI
Vitamin C (mg)
T1: 4.5 to 84.1 ALL 1 1 1
T2: 84.1 to 149.6 1.33 (0.72-2.48) 0.71 (0.40-1.27) 1.23 (0.96-1.57)
T3: 149.6 to 869.6 0.52 (0.23-1.20) 1.07 (0.56-2.03) .44* (1.09-1.91)
T1: 4.5 to 84.1 SR 1 1 1
T2: 84.1 to 149.6 1.21 (0.63-2.34) 1.04 (0.50-2.16) 1.2 (0.84-1.72)
T3: 149.6 to 869.6 0.56 (0.21-1.47) 1.18 (0.51-2.75) 1.28 (0.87-1.90)
Formononetin (mcg)
T1: 0.1 to 9.3 ALL 1 1 1
T2: 9.4 to 23.0 1.08 (0.55-2.15) 47* (0.25-0.89) .27* (1.00-1.61)
T3: 23.1 to 155.6 1.08 (0.46-2.52) 0.79 (0.43-1.43) 1.04 (0.79-1.37)
T1: 0.1 to 9.3 SR 1 1 1
T2: 9.4 to 23.0 1.18 (0.57-2.42) 0.67 (0.29-1.53) 1.16 (0.82-1.63)
T3: 23.1 to 155.6 0.96 (0.41-2.29) 0.56 (0.27-1.14) 1.03 (0.71-1.49)
Genistein (mcg)
T1: 8.1 to 141.3 ALL 1 1 1
T2: 141.7 to 291.3 1.18 (0.57-2.43) 1.18 (0.66-2.12) 1.2 (0.92-1.56)
T3: 291.6 to 44265.2 1.05 (0.40-2.74) 1.25 (0.69-2.27) 1.35* (1.00-1.81)
T1: 8.1 to 141.3 SR 1 1 1
T2: 141.7 to 291.3 0.93 (0.42-2.07) 1.53 (0.71-3.29) 1.02 (0.70-1.48)
T3: 291.6 to 44265.2 0.78 (0.29-2.15) 1.56 (0.65-3.74) 1.42 (0.96-2.10)
Daidzein (mcg)
T1: 10.1 to 269.0 ALL 1 1 1
T2: 270.1 to 440.6 1.77 (0.96-3.26) 0.71 (0.40-1.28) 1.06 (0.83-1.36)
T3: 440.6 to 36886.6 1.7 (0.70-4.14) 1.01 (0.55-1.85) 1.13 (0.86-1.49)
T1: 10.1 to 269.0 SR 1 1 1D
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T2: 270.1 to 440.6 1.54 (0.75-3.17) 1.05 (0.49-2.25) 1.2 (0.84-1.72)
T3: 440.6 to 36886.6 1.21 (0.46-3.20) 0.7 (0.29-1.66) 1.08 (0.75-1.57)
Biochanin A (mcg)
T1: 0.0 to 15.4 ALL 1 1 1
T2: 15.4 to 37.8 1.03 (0.53-2.01) 0.84 (0.47-1.51) 1.27 (0.99-1.62)
T3: 37.8 to 334.7 0.6 (0.28-1.30) 0.91 (0.45-1.88) 1.26 (0.97-1.64)
T1: 0.0 to 15.4 SR 1 1 1
T2: 15.4 to 37.8 1.24 (0.62-2.49) 0.56 (0.26-1.20) 0.92 (0.64-1.33)
T3: 37.8 to 334.7 0.56 (0.24-1.32) 0.66 (0.27-1.57) 1.02 (0.70-1.50)
Calcium (mg)
T1: 85.0 to 499.9 ALL 1 1 1
T2: 501.6 to 807.7 1.23 (0.61-2.47) 0.7 (0.39-1.24) 1.06 (0.82-1.37)
T3: 808.1 to 2686.8 0.95 (0.35-2.53) 1.22 (0.59-2.55) 0.87 (0.64-1.19)
T1: 85.0 to 499.9 SR 1 1 1
T2: 501.6 to 807.7 1.5 (0.70-3.24) 1.32 (0.65-2.67) 1.06 (0.74-1.52)
T3: 808.1 to 2686.8 1.56 (0.58-4.15) 2.27 (0.93-5.53) 0.81 (0.53-1.24)
Folate (mcg)
T1: 56.5 to 297.0 ALL 1 1 1
T2: 297.4 to 434.7 0.45* (0.20-0.99) 1.05 (0.62-1.78) 0.84 (0.65-1.09)
T3: 435.1 to 1530.0 0.35 (0.12-1.01) 0.59 (0.28-1.24) 1.08 (0.78-1.50)
T1: 56.5 to 297.0 SR 1 1 1
T2: 297.4 to 434.7 0.49 (0.22-1.12) 1.29 (0.61-2.73) 0.82 (0.57-1.17)
T3: 435.1 to 1530.0 0.41 (0.13-1.29) 2.26 (0.77-6.60) 1.09 (0.68-1.74)
† adjusted for reporting status (all cases vs self reported cases only), age at diagnosis (<48,48-65,>65), treatment (radiation, chemo, surgery - yes/no), education (<12, 12, >12), marital status (yes/
no), total calories (continuous), pack years (median=18.5), and age at first alcoholic drink (<18,18 - 20,>20).
* p < 0.05
Table 4: Associations between intake of water-soluble antioxidants and survival following glioma diagnosis†, stratified by histology group (Continued)D
e
L
o
r
e
n
z
e
 
e
t
 
a
l
.
 
B
M
C
 
C
a
n
c
e
r
 
2
0
1
0
,
 
1
0
:
2
1
5
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
0
7
/
1
0
/
2
1
5
P
a
g
e
 
1
2
 
o
f
 
1
5
Table 5: Associations of total antioxidant index and macronutrients with glioma survival†, stratified by histology group
Nutrient (unit) Tertiles All or self-report 
(SR) only
Grade II Grade III Grade IV
Lower limit Upper
limit
(143 cases, 72 deaths) (130 cases, 103 deaths) (475 cases, 473 deaths)
HR 95% CI HR 95% CI HR 95% CI
Antioxidant index
T1: 50.1 to 1961.9 ALL 1 1 1
T2: 1963.2 to 3263.0 1.34 (0.70-2.54) 1.31 (0.78-2.18) 1.02 (0.78-1.32)
T3: 3266.1 to 13512.6 0.67 (0.30-1.47) 1.04 (0.58-1.88) 0.36* (1.02-1.81)
T1: 50.1 to 1961.9 SR 1 1 1
T2: 1963.2 to 3263.0 1.41 (0.71-2.80) 1.36 (0.62-2.94) 1.18 (0.82-1.68)
T3: 3266.1 to 13512.6 0.74 (0.31-1.77) 1.03 (0.49-2.16) 1.07 (0.72-1.59)
Total Protein (g)
T1: 11.4 to 49.5 ALL 1 1 1
T2: 49.6 to 70.8 0.44* (0.20-0.95) 1.44 (0.75-2.74) 1.08 (0.83-1.40)
T3: 71.1 to 241.5 0.32 (0.10-1.04) 1.73 (0.78-3.83) 0.64* (0.43-0.95)
T1: 11.4 to 49.5 SR 1 1 1
T2: 49.6 to 70.8 0.40* (0.18-0.93) 1.57 (0.74-3.31) 1.13 (0.78-1.62)
T3: 71.1 to 241.5 0.53 (0.15-1.81) 1.18 (0.42-3.27) 0.88 (0.52-1.50)
Total Fat (g)
T1: 10.2 to 47.1 ALL 1 1 1
T2: 47.2 to 72.7 1.33 (0.60-2.96) 0.77 (0.43-1.38) 1.13 (0.87-1.47)
T3: 72.9 to 213.0 0.88 (0.29-2.66) 0.73 (0.35-1.51) 1.10 (0.74-1.63)
T1: 10.2 to 47.1 SR 1 1 1
T2: 47.2 to 72.7 1.10 (0.47-2.54) 0.67 (0.29-1.53) 1.06 (0.73-1.53)
T3: 72.9 to 213.0 0.81 (0.26-2.53) 0.74 (0.30-1.85) 1.11 (0.61-2.01)
Total Cholesterol (mg)
T1: 17.2 to 166.1 ALL 1 1 1
T2: 166.2 to 272.7 0.53 (0.24-1.14) 0.86 (0.49-1.49) 1.50* (1.17-1.93)
T3: 273.0 to 1322.0 0.76 (0.31-1.86) 0.49* (0.25-0.95) 1.31 (0.97-1.78)
T1: 17.2 to 166.1 SR 1 1 1
T2: 166.2 to 272.7 0.59 (0.25-1.41) 1.04 (0.53-2.03) 1.39 (0.98-1.97)
T3: 273.0 to 1322.0 1.00 (0.38-2.59) 0.68 (0.28-1.63) 1.13 (0.71-1.80)
† adjusted for reporting status (all cases vs self reported cases only), age at diagnosis (<48,48-65,>65), treatment (radiation, chemo, surgery - yes/no), education (<12, 12, >12), marital status (yes/
no), total calories (continuous), pack years (median = 18.5), and age at first alcoholic drink (<18,18-20,>20).
* p < 0.05DeLorenze et al. BMC Cancer 2010, 10:215
http://www.biomedcentral.com/1471-2407/10/215
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secoisolariciresinol; modertate intake of formononetin,
matairesinol and total cholesterol; moderate and high
intake of cryptoxanthin. Moderate intake of total protein
was associated with significantly enhanced survival. That
significant results were not observed in the self-reported
cases only may indicate systematic misclassification
errors attributable to proxy respondents who were not
entirely accurate in recalling the case's dietary habits, or
to cases that were too ill to recall their actual eating pat-
terns with clarity. The hazard ratios for secoisolaricires-
inol and formononetin in the Grade IV group are in the
opposite direction from the corresponding hazard ratios
estimated among Grade II and Grade II patients. While
such difference could be due to chance, it does highlight
the need for stratifying data analyses by histology group,
which is a strength of the current study. Moreover, histol-
ogy Grades III and IV have shorter survival following
diagnosis of glioma than Grade II; and Grade IV, which
has almost 100% mortality within 5 years of diagnosis, is
also distinguished from Grade III. Therefore, the diet
prior to diagnosis is closer to time of death for higher
than lower Grade glioma patients.
The difference in the associations between antioxidants
and survival of patients with different glioma grades may
be explained by the specific tumor biology, differences in
the interaction between the treatment and antioxidants,
or by chance. There are several indications that the
detected associations can not be explained by chance
alone. Where the same antioxidant\nutrient was signifi-
cant in more than one grade, the hazard ratios were gen-
e r a l l y  i n  t h e  s a m e  d i r e c t i o n  i n  s e v e r a l  i n s t a n c e s :  o n e
example is the association with lycopene among Grade II
and Grade III patients; another example is total protein in
Grade II and Grade IV patients.
Statistically significant results were not confined to one
particular subclass of antioxidants, but were found
among isoflavones (e.g. genistein), carotenoids (e.g. lyco-
pene), lignans (e.g. matairesinol), vitamin C, vitamin E
and folate. Our study also observed significant results
among both fat- and water- soluble antioxidants.
Our study used patients' responses to a diet question-
naire as the primary data source for converting this infor-
mation into grams of specific antioxidant consumed per
day by applying an appropriate algorithm. We recognize
that internal exposure dose (usually measured as plasma
concentration) to antioxidants may be confounded by
individual difference in absorption. However, at least for
carotinoids, a correlation has been demonstrated
between questionnaire-derived intake and plasma levels
[57,58].
Recent developments in treatment of malignant
gliomas have provided some extension of survival time
through the concomitant administration of temozolo-
mide (TMZ) chemotherapy following surgery and radio-
therapy [59]. Since our study cohort preceded the
widespread introduction of TMZ as standard of care for
glioblastoma (grade IV) in 2005, the enhanced survival
associated with TMZ use is not reflected in this patient
cohort. However a strength of our study is that the asso-
ciation between dietary antioxidants and glioma patient
survival is not confounded by patients receiving TMZ.
Given the large number of associations examined, we
acknowledge that some findings may be merely due to
chance. Although there remains controversy regarding
the use of some adjustment for multiple associations or
comparisons in observational studies (e.g. Bonferroni), it
is our position not to use them. We base our decision in
part on the rationale outlined by Rothman [60] and Savitz
[61]. Rothman asserts that the adjustment, while decreas-
ing type I error, would increase the risk of type II error for
associations that are not null. He furthermore states that
"a policy of not making adjustment for multiple compari-
sons is preferable because it will lead to fewer errors of
interpretation when the data under evaluation are not
random numbers but actual observations on nature". As
recommended, we have made clear the number and
nature of statistical tests, allowing audiences their own
interpretation of study findings.
Conclusions
The associations observed in our study suggest that the
influence of some non-enzymatic antioxidants on sur-
vival following a diagnosis of malignant glioma are incon-
sistent and vary by histology group. In the same cohort of
glioma patients, a case-control study found a number of
significant inverse associations between antioxidant
intake and gliomagenesis [46]; however our current study
of antioxidant intake and glioma survival did not observe
the same number of inverse associations. Further
research in a large sample of glioma patients is needed to
confirm or refute our study results.
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